Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia.

Kroesen M, Mulder HT, van Holthe JML, Aangeenbrug AA, Mens JWM, van Doorn HC, Paulides MM, Oomen-de Hoop E, Vernhout RM, Lutgens LC, van Rhoon GC, Franckena M.

Radiother Oncol. 2019 Jul 11;140:150-158. doi: 10.1016/j.radonc.2019.06.021. [Epub ahead of print]

PMID:
31302345
2.

The Effect of the Time Interval Between Radiation and Hyperthermia on Clinical Outcome in 400 Locally Advanced Cervical Carcinoma Patients.

Kroesen M, Mulder HT, van Holthe JML, Aangeenbrug AA, Mens JWM, van Doorn HC, Paulides MM, Oomen-de Hoop E, Vernhout RM, Lutgens LC, van Rhoon GC, Franckena M.

Front Oncol. 2019 Mar 8;9:134. doi: 10.3389/fonc.2019.00134. eCollection 2019.

3.

Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.

Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M.

Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311.

4.

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ.

Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13.

5.

Training Medical Specialists to Communicate Better with Patients with Medically Unexplained Physical Symptoms (MUPS). A Randomized, Controlled Trial.

Weiland A, Blankenstein AH, Van Saase JL, Van der Molen HT, Jacobs ME, Abels DC, Köse N, Van Dulmen S, Vernhout RM, Arends LR.

PLoS One. 2015 Sep 18;10(9):e0138342. doi: 10.1371/journal.pone.0138342. eCollection 2015.

6.

Training specialists to write appropriate reply letters to general practitioners about patients with medically unexplained physical symptoms; A cluster-randomized trial.

Weiland A, Blankenstein AH, Willems MH, Van Saase JL, Van Daele PL, Van der Molen HT, Langbroek GB, Bootsma A, Vriens EM, Oberndorff-Klein Woolthuis A, Vernhout RM, Arends LR.

Patient Educ Couns. 2015 Oct;98(10):1229-35. doi: 10.1016/j.pec.2015.06.021. Epub 2015 Jul 2.

7.

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp HM, Walenkamp AM, Beerepoot L, Hanse M, van Linde ME, Otten A, Vernhout RM, de Vos FY, Gratama JW, Sleijfer S, van den Bent MJ.

Br J Cancer. 2015 Jul 14;113(2):226-31. doi: 10.1038/bjc.2015.191. Epub 2015 Jun 4.

8.

Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?

Scholten ET, de Jong PA, de Hoop B, van Klaveren R, van Amelsvoort-van de Vorst S, Oudkerk M, Vliegenthart R, de Koning HJ, van der Aalst CM, Vernhout RM, Groen HJ, Lammers JW, van Ginneken B, Jacobs C, Mali WP, Horeweg N, Weenink C, Thunnissen E, Prokop M, Gietema HA.

Eur Respir J. 2015 Mar;45(3):765-73. doi: 10.1183/09031936.00005914. Epub 2014 Nov 27. Erratum in: Eur Respir J. 2015 May;45(5):1517.

9.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
10.

Peptides from the variable region of specific antibodies are shared among lung cancer patients.

de Costa D, Broodman I, Calame W, Stingl C, Dekker LJ, Vernhout RM, de Koning HJ, Hoogsteden HC, Sillevis Smitt PA, van Klaveren RJ, Luider TM, Vanduijn MM.

PLoS One. 2014 May 1;9(5):e96029. doi: 10.1371/journal.pone.0096029. eCollection 2014.

11.

The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules.

van 't Westeinde SC, Horeweg N, Vernhout RM, Groen HJM, Lammers JJ, Weenink C, Nackaerts K, Oudkerk M, Mali W, Thunnissen FB, de Koning HJ, van Klaveren RJ.

Chest. 2012 Aug;142(2):377-384. doi: 10.1378/chest.11-2030.

PMID:
22302298
12.

A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer.

Surmont V, Aerts JG, van Klaveren RJ, Tournoy K, Tan KY, Vernhout RM, Schmitz PI, Legrand C, Hoogsteden HC, van Meerbeeck JP.

Oncology. 2010;78(3-4):267-70. doi: 10.1159/000315733. Epub 2010 Jun 7.

PMID:
20523087
13.

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.

van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ.

J Thorac Oncol. 2006 Jan;1(1):25-30.

14.

Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial.

van Tongeren RB, van Sambeek MR, van Overhagen H, Coen VL, Schmitz PI, Gescher FM, Wittens CH, Vernhout RM, van Urk H, Levendag PC, Bruijninckx CM.

J Cardiovasc Surg (Torino). 2005 Aug;46(4):437-43.

PMID:
16160691
15.

External beam radiation therapy to prevent anastomotic intimal hyperplasia in prosthetic arteriovenous fistulas: results of a randomized trial.

van Tongeren RB, Levendag PC, Coen VL, Schmitz PI, Gescher FM, Vernhout RM, Wittens CH, Bruijninckx CM.

Radiother Oncol. 2003 Oct;69(1):73-7.

PMID:
14597359

Supplemental Content

Loading ...
Support Center